Three-month early change in prostate-specific antigen levels as a predictive marker for overall survival during hormonal therapy for metastatic hormone-sensitive prostate cancer

To date, there are no useful markers for predicting the prognosis of metastatic hormone-sensitive prostate cancer (mHSPC). We evaluated the effect of early changes in prostate-specific antigen (PSA) levels aft...

Source: BMC Research Notes - June 3, 2021 Category: Research Authors: Shotaro Nakanishi, Masato Goya, Mitsuyoshi Tamaki, Takuma Oshiro and Seiichi Saito Tags: Research note Source Type: research